Biomira appoints industry veteran as Chief Operating Officer
17 Julio 2007 - 7:00AM
PR Newswire (US)
EDMONTON, July 17 /PRNewswire-FirstCall/ -- Biomira Inc.
(NASDAQ:BIOM) (TSX: BRA) today announced the appointment of Gary
Christianson to the newly created position of Chief Operating
Officer. Mr. Christianson brings to Biomira more than 20 years of
operational expertise in diverse areas, including technical
development, manufacturing of pharmaceutical products, facilities
design and management, and personnel development. "Gary's extensive
operational expertise will be an important asset as we work to
realize the potential of our expanding pipeline," said Dr. Robert
L. Kirkman, M.D., President and Chief Executive Officer of Biomira.
"Biomira is responsible for all manufacturing activities for our
Phase 3 vaccine, Stimuvax(R), including process scale-up for
commercialization, and Gary has the background to lead this effort.
With PX-12 in Phase 2, PX-478 expected to enter Phase 1 this
quarter, and an Investigational New Drug application planned for
PX-866 by year's end, there are also multiple technical development
and manufacturing activities for our small molecule pipeline. In
addition, I expect that Gary will play a significant role in
developing strategies to integrate our multi-site activities and to
maximize our efficiency, productivity and capabilities. We are
pleased to welcome him to the Biomira team." Mr. Christianson said,
"I am very excited to join Biomira and believe that its development
pipeline holds numerous opportunities to make a difference in the
lives of cancer patients. I look forward to working with the rest
of the Biomira management team to create value for patients and for
the Company's investors." Mr. Christianson was, most recently, Site
Director for GlaxoSmithKline's (GSK) Biologics Unit in Hamilton,
Montana. In this position, he oversaw staffing and planning for a
250-person facility that manufactured a key component of several
GSK vaccines. Previously, he spent six years as Vice President,
Technical Operations at Corixa Corp., including two years as a
General Manager. In addition to facility and personnel
responsibilities at Corixa, Mr. Christianson also oversaw
production of Bexxar(R) (Tositumomab and Iodine I 131 Tositumomab),
an approved cancer therapy. From 1987 to 1999, Mr. Christianson
held positions of increasing responsibility at RIBI ImmunoChem
Research, rising to Director, Production and Engineering. He
received a B.S. in Mechanical Engineering Technology from Montana
State University and is a Licensed and Board Certified Professional
Engineer. He is a member of numerous professional organizations,
including the International Society for Pharmaceutical Engineers
and the Parenteral Drug Association. About Biomira Biomira is a
biotechnology company specializing in the development of innovative
therapeutic products for the treatment of cancer. Biomira's goal is
to develop and commercialize novel synthetic vaccines and targeted
small molecules that have the potential to improve the lives and
outcomes of cancer patients. Forward-Looking Statements This press
release contains forward looking statements, including, without
limitation, statements related to drug candidates in Biomira's
pipeline; future clinical development plans; the details of the
clinical trials; and the anticipated manufacturing activities for
Stimuvax and other Biomira product candidates. Any statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"will," "intends," "potential," "possible" and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements are based upon Biomira's current
expectations. Forward-looking statements involve risks and
uncertainties. Various factors could cause actual results to differ
materially from those projected in forward-looking statements,
including those predicting the timing, duration and results of
clinical trials, the anticipated manufacturing activities for
Biomira product candidates, and the possibility of future
commercialization of any Biomira product. There can be no guarantee
that the results of earlier trials will be predictive of either
safety or efficacy in future trials. Biomira expressly disclaims
any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in the company's expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based. DATASOURCE: Biomira Inc.
CONTACT: Investor and Media Relations Contact: Robert Kirkman,
M.D., Chief Executive Officer, Biomira, (780) 490-2800,
Copyright
Biomira Inc. - Common Shares (MM) (NASDAQ:BIOM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Biomira Inc. - Common Shares (MM) (NASDAQ:BIOM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024